购物车
- 全部删除
- 您的购物车当前为空
YJ1206 是一种选择性CDK12/CDK13 PROTAC降解剂,具备口服活性,在VCaP细胞中展示出12.55 nM的IC50值。该化合物能够增加DNA损伤,诱导细胞凋亡,并在抗药性前列腺癌PDX小鼠模型(WA74来源)中促进肿瘤消退。此外,YJ1206可与AKT通路抑制剂协同,有效抑制体内肿瘤的生长。
YJ1206 是一种选择性CDK12/CDK13 PROTAC降解剂,具备口服活性,在VCaP细胞中展示出12.55 nM的IC50值。该化合物能够增加DNA损伤,诱导细胞凋亡,并在抗药性前列腺癌PDX小鼠模型(WA74来源)中促进肿瘤消退。此外,YJ1206可与AKT通路抑制剂协同,有效抑制体内肿瘤的生长。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 期货 | |
50 mg | 询价 | 期货 |
产品描述 | YJ1206 is a selective CDK12/CDK13 PROTAC degrader with oral activity, demonstrating an IC50 of 12.55 nM in VCaP cells. It enhances DNA damage, induces apoptosis, and promotes tumor regression in a castration-resistant prostate cancer PDX (patient-derived xenograft) mouse model derived from original site WA74. Additionally, YJ1206 acts synergistically with AKT pathway inhibitors to suppress in vivo tumor growth. |
分子量 | 894.01 |
分子式 | C49H52FN11O5 |
CAS No. | 3053716-98-3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容